Subgroup analyses revealed important differences based on comparator drugs: GLP-1RAs demonstrated greater effectiveness than SGLT2 inhibitors in preventing MALOs (IRR: 0.93, 95%CI: 0.87-0.99, P = 0.043), than DPP-4 inhibitors in preventing hepatic decompensation events (IRR: 0.74, 95%CI: 0.66-0.83, P = 0.003), and than insulin therapy in averting HCC development (IRR: 0.32, 95%CI: 0.13-0.80, P = 0.033) [64]
Conclusions This study analyzed public Facebook posts to examine public discussion of adverse events associated with GLP-1 RAs from 2022 to 2024
If they don't make it past your digestive tract, they can't help your skin
Table of Contents: What does a B12 shot do for you
within this subgroup, all outcomes improved significantly at M6
However, these side effects are temporary and will resolve within hours of the treatment